{"anticipatedPostingDate":"2026-09","denomUnitsSelected":"Participants","description":"The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs), Serious Adverse Event (TESAEs) and Deaths due to AEs, through the monitoring of relevant clinical and laboratory safety parameters. Treatment emergent adverse events falling into the category of myelosuppression, renal toxicity or second malignancy will be recorded beyond 30 day safety observation period.","reportingStatus":"NOT_POSTED","timeFrame":"From randomization till 30 day safety follow-up, assessed up to 43 months (estimated final OS analysis).","title":"Number of Participants With Treatment Emergent Adverse Events","type":"SECONDARY"}